[32]  Clinical data from 137 2019-nCoV- infected patients  Patients were treated symptomatically and given respiratory support. Immunoglobulin was given to few patients depending upon clinical severity and response. No benefit was observed from systematic corticosteroid. Notably, early respiratory support facilitated disease recovery and improved prognosis. The risk of death was primarily associated with age, underlying chronic diseases, and median interval from the appearance of initial symptoms to dyspnea  Patients with higher age at presentation and concomitant disease were more likely to show features of respiratory failure and had poorer outcome